Japanese Safety Pharmacology Society Meeting of Promoters September 5 th, 2009 Keiji Yamamoto, DVM,...
-
Upload
audra-miles -
Category
Documents
-
view
214 -
download
2
Transcript of Japanese Safety Pharmacology Society Meeting of Promoters September 5 th, 2009 Keiji Yamamoto, DVM,...
Japanese Safety Japanese Safety Pharmacology SocietyPharmacology Society
Meeting of PromotersSeptember 5th, 2009
Keiji Yamamoto, DVM, MBA, PhD
Attendees – a total of 16Attendees – a total of 16
K. Yamamoto (Takeda Pharmaceutical)M. Tabo (Chugai)T. Kitayama (Kyowahakko-Kirin)H. Tashibu (Dainippon-Sumitomo)C, Kasai (Astellas)S. Toyoshima (Ootsuka)M. Wasaki (Mitsubishi-Tanabe)T. Hombo (Ina Research)K. Chiba (Daiichi-Sankyo)S. Hayashi (Nippon Shinyaku)6 Observers
Name, OrganizationName, Organization
Japanese Safety Pharmacology Society (JSPS)
Agreed to establish as an independent and non-profit organization
Main activity is to hold an annual meetingmay develop cooperative relationship with
other societies◦Safety Pharmacology Society◦Japan Society of Toxicology◦Japanese Society of Pharmacology
BoD members BoD members
Pharmaceutical companies (~10)CROs (~3)Academia (~3)
◦ Dr. Hashimoto (Yokohama Yakka Univ)◦ Dr. Tsubone (Tokyo Univ)◦ Dr. Sugiyama (Yamanashi Univ)
Regulatory agency (at least 1)◦ Dr. Ohno (NIHS)◦ Dr. Nakazawa (NIHS)◦ ?? (PMDA)
Rules will be revised in 2 years
Main activityMain activity
Annual meeting in Japan. The 1st meeting will be in February 2010
◦50-100 attendees expected 2.5 SPs/industry x 30 companies 1 Toxs/industry x 30 companies 10 persons from Academia 5 persons from Regulatory (invited)
Organizer Company
1st Meeting (Feb 2010) Keiji Yamamoto Takeda
2nd Meeting (Feb 2011) Masahiko Wasaki Tanabe-Mitsubishi
3rd Meeting (Feb 2012) Chieko Kasai Astellas
4th Meeting (Feb 2013) Katsuyoshi Chiba Daiichi-Sankyo
Meeting TopicsMeeting Topics
Scientific session (Oral only?)Symposium
◦Merge toxicity study with safety pharmacology studies: Why, When, Who and How? Need mutual education between Tox- & SP gists
◦New tools for safety pharmacology: iPS, Non-invasive SP methods
◦Disease model for risk in specific patient population
Topics (continued)Topics (continued)
Regulatory session◦ICH guidelines (S6, S9, E14 and S7B, M3 and
vaccine)◦An official guide book for ICH guidelines will be
published in June 2010 (Activity has started since June 2009 NIHS/PMDA/JPMA)
Relation with SPSRelation with SPS
K. Yamamoto will explain the situation in Japan in the coming SPS meeting.